Actively Recruiting
Evaluating Avacopan TAVNEOS in Adults with Active Ear, Nose, and Throat Disease from Granulomatosis With Polyangiitis Using Standard Care Plus Randomized Treatment
Led by Robert Spiera, MD · Updated on 2026-09-02
30
Participants Needed
2
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of TAVNEOS in adults with Granulomatosis With Polyangiitis GPA who have active ear, nose, and throat ENT disease affecting at least two ENT areas. This randomized, double-blind, placebo-controlled study compares TAVNEOS with placebo alongside standard care to assess remission rates and disease activity over one year. Participants will receive either a 30 mg twice daily dose of TAVNEOS or a matching placebo in addition to their usual treatment as determined by their rheumatologist. The study lasts 52 weeks with regular standardized ENT exams and rheumatologic assessments using the Birmingham Vasculitis Activity Score BVAS. The trial is conducted at a single center and includes detailed ENT evaluations performed by an expert otolaryngologist. During the study, participants will undergo periodic ENT and overall disease activity assessments. Researchers will monitor remission status, changes in disease scores, steroid use, and flare occurrences. Patient-reported outcomes and quality of life measures related to ENT symptoms will also be collected. Safety and treatment effects will be evaluated over approximately 60 weeks, including follow-up for surgical needs and relapses.
CONDITIONS
Brief Title
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Research Team
L
Liza M Morales, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here